Search Results for "Colchicine And Rivaroxaban"

12:01 EDT 21st August 2014 | BioPortfolio

Original Source: Targeting Inflammation in Acute Coronary Syndrome Using Colchicine

The purpose of this study is to evaluate the effect of colchicine on high sensitivity C-reactive protein (hs-CRP), a blood marker to measure inflammation, in patients with acute coronary syndromes.

Matching Channels

Rivaroxaban

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

Colchicine Can Treat Full Range of Pericarditis

Low-dose colchicine should be a first-line treatment for either acute or recurrent pericarditis, report investigators of a double-blind study that randomized 240 patients with recurrent pericarditis t...

Pharmacotherapy: Colchicine for recurrent pericarditis—what's new in CORP-2?

In the CORP-2 trial, patients with multiple recurrences of idiopathic or autoimmune pericarditis were randomly assigned to receive colchicine or placebo, in addition to standard anti-inflammatory ther...

[Articles] Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial

Colchicine added to conventional anti-inflammatory treatment significantly reduced the rate of subsequent recurrences of pericarditis in patients with multiple recurrences. Taken together with results...

Colchicine Cuts Multiple Recurrences of Pericarditis: CORP 2

Already shown to reduce recurrences in patients with a new diagnoses of pericarditis, colchicine has now also demonstrated benefits in preventing multiple recurrences. Heartwire

BRIEF-Bayer initiates two phase III trials with rivaroxaban in medically-ill patients and children at high risk of blood clots

FRANKFURT, March 31 (Reuters) - Bayer AG : * Says initiates two phase III trials with Rivaroxaban in medically-ill

CORP-2 trial and the role of colchicine in nonidiopathic pericarditis

Janssen expands global cardiovascular research program with three new studies

Janssen R&D is adding three new clinical trials to its EXPLORER global cardiovascular research program for XARELTO (rivaroxaban), a broadly indicated oral Factor Xa inhibitor. The additional trials wi...

Xarelto rivaroxaban: Phase III started

Matching PubMed Articles

Rivaroxaban and Hemostasis in Emergency Care.

Rivaroxaban is an oral, direct Factor Xa inhibitor, approved for the prevention and treatment of several thromboembolic disorders. Rivaroxaban does not require routine coagulation monitoring and has a...

Colchicine for the prevention of pericarditis: what we know and what we do not know in 2014 - systematic review and meta-analysis.

The purpose of this study was to investigate and summarize available evidence on the efficacy and safety of colchicine for pericarditis prevention. Disease recurrence is the major and most common comp...

Efficacy and safety of rivaroxaban versus low-molecular-weight heparin therapy in patients with lower limb fractures.

Thromboprophylaxis with rivaroxaban has proved effective and safe in patients undergoing hip and knee replacement surgery. As it is unclear whether it is also effective and safe in fracture patients,...

Colchicine in Behcet Syndrome: A Longterm Survey of Patients in a Controlled Trial.

To test the hypothesis that colchicine use during early disease decreases immunosuppressive use in Behçet syndrome (BS) in the long term.

Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.

Knowledge of anticoagulation status during rivaroxaban therapy is desirable in certain clinical situations. It was the study objective to determine coagulation tests most useful for assessing rivaroxa...

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement